ArticleFrontiers in endocrinology2022

Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.

Mario Detomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.